Treatment of skin disorders

Abstract

The present invention relates to a compound of formula (I), wherein X, Xand Xare, independently of each other, N or CH; with the proviso that at least two of XXand Xare N; Y is N or CH; W is H or F; with the proviso that when W is F, then Xi, Xand Xare N; Rand Rare independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein Rand Rare independently of each other H, C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-Calkoxy, C-CalkoxyC-Calkyl, CN, or C(O)O—C-Calkyl; or Rand Rform together a bivalent residue —RR— selected from C-Calkylene optionally substituted with 1 to 4 F, —CH—O—CH—, —CH—NH—CH—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R; wherein Ris independently at each occurrence C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-CalkoxyC-Calkyl, C-Ccycloalkyl; or two Rsubstituents form together a bivalent residue —RR— selected from C-Calkylene optionally substituted with 1 to 4 F, —CH—O—CH— or —O—CHCH—O—; with the proviso that at least one of Rand Ris a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.